Etidronate is a medication being studied to see if it can stop or slow down the worsening of cognitive functions in patients with Fahr’s disease or syndrome. This condition involves abnormal calcium deposits in the brain, and the trial aims to find out if etidronate can help manage these deposits and improve or maintain brain function.

Fahr’s Syndrome – Fahr’s syndrome is a rare neurological disorder characterized by abnormal calcium deposits in areas of the brain that control movement. These deposits can lead to a variety of symptoms, including movement disorders, cognitive decline, and psychiatric issues. The condition often begins in adulthood, but symptoms can vary widely among individuals. As the disease progresses, patients may experience difficulties with coordination, speech, and balance. The exact cause of Fahr’s syndrome is not well understood, but it is believed to have a genetic component. The progression of symptoms can be gradual, affecting daily functioning and quality of life over time.

Fahr’s Disease – Fahr’s disease is a genetic disorder that results in abnormal calcium buildup in the brain, particularly in the basal ganglia and other areas responsible for motor control. This condition can lead to a range of neurological symptoms, such as tremors, muscle stiffness, and involuntary movements. Cognitive impairment and psychiatric symptoms, such as mood swings or depression, may also occur. The onset of symptoms typically occurs in adulthood, but the severity and progression can vary. Over time, individuals may experience increasing difficulty with movement and coordination. The underlying genetic mutations associated with Fahr’s disease are still being studied to better understand its development.